Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis.
about
Recent insights into the role of autophagy in the pathogenesis of rheumatoid arthritisPreclinical rheumatoid arthritis (autoantibodies): an updated reviewPathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLEWhen and where does inflammation begin in rheumatoid arthritis?Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigationThe likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk.Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives.Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.Contributions of familial rheumatoid arthritis or lupus and environmental factors to risk of rheumatoid arthritis in women: a prospective cohort studyAlcohol consumption and markers of inflammation in women with preclinical rheumatoid arthritisImproved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history.Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease?Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk geneGene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.Environmental and gene-environment interactions and risk of rheumatoid arthritis.Physical Characteristics of a Citrullinated Pro-Filaggrin Epitope Recognized by Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Sera.Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis.Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls.Ambient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-control studyAmbient air pollution exposures and risk of rheumatoid arthritis.Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.Association of environmental and genetic factors and gene-environment interactions with risk of developing rheumatoid arthritis.Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established diseaseCan rheumatoid arthritis be prevented?Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis.Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool.The case for measuring antibodies to specific citrullinated antigens.Defining populations at risk of rheumatoid arthritis: the first steps to prevention.Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis.Mechanisms involved in triggering rheumatoid arthritis.How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study.Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis.Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis-related autoimmunityPredicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study.Anticitrullinated protein/peptide antibodies and rheumatoid factors: two distinct autoantibody systems.The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed?Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients.The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis.
P2860
Q26784021-7DF90DF3-2530-43E8-A806-3F7BD24D746AQ26863441-E2F1443D-9911-4086-8422-244096C8E43EQ27003201-92F05DBE-0F74-4496-A17A-96FC830B621FQ33662199-F258CA3A-E5D7-48AC-8143-2604E3D63AB3Q33890221-AD8BC415-3DF7-49DB-9542-958448415CBFQ34027412-21C59879-E0BE-40BB-B492-1A28C93F34DBQ34103237-6409D925-78F8-4B0B-9380-ECCF884F9A4CQ34244089-5A95FC64-2B7F-480C-A969-781661656880Q34250833-349DC1E8-034C-43EC-8C4B-A72893117647Q34254675-CA1C3DAF-30A2-405C-9655-26ECB0B7072CQ34372743-541322E3-2F5C-4542-8377-5DEFCF3A1F4EQ34675012-38A455ED-003C-4300-B05C-B889983621E3Q35059538-4C8FE95A-10E4-4614-9543-E0942B8C9BB5Q35092644-CEBAB113-CB2F-4BCD-B0AE-53A5F0A3A3E3Q35533807-F1295D4D-ABE9-4E7B-BE03-BAFE11B5326EQ36110733-E7062409-EF20-477F-9388-FCE6E548CD5DQ36230539-09EF75AA-C754-4A3D-8233-1AC796C151B0Q36245951-F2AFD8AF-CC46-410E-A631-7FC77F1974B9Q36639920-38E4A7C7-2700-4827-B4EA-F470EEF36E60Q36844067-9C6F1FCC-50B6-4F1D-B82B-B8D5E2F92FD0Q36859711-FAFAC9C2-C2A0-4918-B94A-E32538D7884EQ36903191-584ACC4A-3EDC-402E-9C2C-2D2E5FED8E6EQ37087883-7EADE528-889A-4046-B720-170FF6D2849DQ37179639-62700C8E-51E4-415D-A988-3B61DD95F2C9Q37589108-C84179A8-9FBD-41C3-A367-68BCA39E16FAQ37898025-F72DA138-9C74-407C-9865-8338EADC0018Q38078245-1D0A8D98-989E-4CC4-B3CE-2F867A85C119Q38161557-8A56208F-17D5-4ED2-8A9A-1245A3C22EA5Q38220638-378AF1FB-3942-471D-8617-5124D056F832Q38235035-F56191DA-3B4C-44EA-B982-86E0C1057E94Q38673425-6D3B7118-6669-4AB9-9AEC-00A199B56F72Q39812962-829F259A-5E16-40E2-B635-4CF39B5EA173Q40513222-6AA8C2D3-7ACB-4CBC-AF96-46A16A7DFCE4Q42371035-F204873C-5946-4BBE-AA7D-676B2D70276CQ42423867-D14A02CB-698C-463E-AE48-44E41AF2DFF2Q42654393-BDEA01CC-B31A-4F29-BAA2-692A9EB8AD4BQ42692933-9BF60BB4-71C2-4EB4-8B7D-BB92490CC9C8Q44071398-2D3CD1A8-99B0-48B5-8825-B7F42F3F9B4BQ44500351-A3839FFA-5329-462F-A7AF-08169957CEC2Q50308665-8DA60872-3FD8-4D6E-B7AF-F06245B41406
P2860
Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@ast
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@en
type
label
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@ast
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@en
prefLabel
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@ast
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Comparison of threshold cutpoi ...... g future rheumatoid arthritis.
@en
P2093
Elizabeth W Karlson
Karen H Costenbader
Lisa A Mandl
Lori B Chibnik
Peter H Schur
P2860
P304
P356
10.3899/JRHEUM.080895
P407
P577
2009-02-17T00:00:00Z